Cue Biopharma Announces Pricing of Public Offering
Boston, MA – April 14, 2025 – Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company specializing in the development of novel therapeutic biologics for cancer and autoimmune diseases, recently announced the pricing of a public offering. The offering includes:
- 13,530,780 shares of common stock and accompanying common stock warrants to purchase 3,382,695 shares of common stock
- To certain investors, pre-funded warrants to purchase 11,469,216 shares of common stock and accompanying common stock warrants to purchase 2,867,304 shares of common stock
Each share of common stock and accompanying common stock warrant will be sold at a combined public offering price of $0.79.
In lieu of common stock, pre-funded warrants will be sold at a combined public offering price of $0.789. The aggregate gross proceeds from the offering are predicted to be around $20 million, excluding underwriting discounts, commissions, and other offering expenses.
Details of the Offering
Each pre-funded warrant will have an exercise price of $0.001 per share and will become exercisable immediately. They will remain exercisable until all pre-funded warrants have been exercised in full. Each common stock warrant will have an exercise price of $0.79 per share, will also become exercisable immediately, and will expire five years from the issuance date.
The offering is scheduled to close on or about April 16, 2025, contingent upon fulfilling customary closing conditions.
Impact on Individual Investors
For individual investors considering purchasing Cue Biopharma stock during this public offering, it is essential to conduct thorough research and consider consulting with a financial advisor. Factors such as the company’s financial health, market conditions, and competition within the biopharmaceutical industry should be taken into account before making an investment decision.
Global Implications
The biopharmaceutical sector continues to innovate and evolve, with a growing focus on precision medicine and targeted therapies. Cue Biopharma’s announcement of a public offering could have implications for the industry as a whole, potentially leading to increased competition and investment in research and development.
Additionally, the success of Cue Biopharma’s offerings could impact investor sentiment towards the biotech sector, potentially driving increased interest and investment in companies developing novel therapeutics for cancer and autoimmune diseases.
Conclusion
Cue Biopharma’s recent announcement of a public offering marks an exciting development for the clinical-stage biopharmaceutical company, with potential implications for individual investors and the biopharmaceutical industry as a whole. As always, it is crucial for investors to conduct thorough research and consider consulting with a financial advisor before making any investment decisions.
